key: cord-0969230-wauln7vr
authors: de Alwis, Ruklanthi; Gan, Esther S; Chen, Shiwei; Leong, Yan Shan; Tan, Hwee Cheng; Zhang, Summer L; Yau, Clement; Matsuda, Daiki; Allen, Elizabeth; Hartman, Paula; Park, Jenny; Alayyoubi, Maher; Bhaskaran, Hari; Dukanovic, Adrian; Bao, Belle; Clemente, Brenda; Vega, Jerel; Roberts, Scott; Gonzalez, Jose A.; Sablad, Marciano; Yelin, Rodrigo; Taylor, Wendy; Tachikawa, Kiyoshi; Parker, Suezanne; Karmali, Priya; Davis, Jared; Sullivan, Sean M.; Hughes, Steve G.; Chivukula, Pad; Ooi, Eng Eong
title: A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice
date: 2020-09-03
journal: bioRxiv
DOI: 10.1101/2020.09.03.280446
sha: 304fb2a1a0ae392ea6d2338ae8d86aebfa89be8a
doc_id: 969230
cord_uid: wauln7vr

A self-transcribing and replicating RNA (STARR™) based vaccine (LUNAR®-COV19) has been developed to prevent SARS-CoV-2 infection. The vaccine encodes an alphavirus-based replicon and the SARS-CoV-2 full length spike glycoprotein. Translation of the replicon produces a replicase complex that amplifies and prolong SARS-CoV-2 spike glycoprotein expression. A single prime vaccination in mice led to robust antibody responses, with neutralizing antibody titers increasing up to day 60. Activation of cell mediated immunity produced a strong viral antigen specific CD8+ T lymphocyte response. Assaying for intracellular cytokine staining for IFN-γ and IL-4 positive CD4+ T helper lymphocytes as well as anti-spike glycoprotein IgG2a/IgG1 ratios supported a strong Th1 dominant immune response. Finally, single LUNAR-COV19 vaccination at both 2 μg and 10 μg doses completely protected human ACE2 transgenic mice from both mortality and even measurable infection following wild-type SARS-CoV-2 challenge. Our findings collectively suggest the potential of Lunar-COV19 as a single dose vaccine.

(depicted as red and orange spheres in Figure 2D -F), indicating clear differences in immune 151 gene expression between LUNAR-COV19 vaccinated and placebo groups. These trends were 152 also dissimilar to those from mice given conventional mRNA vaccine where at all tested 153 doses, the PCA displayed substantial overlap with PBS control (shown as blue and orange 154 spheres in Figure 2D 

We next investigated the cellular immune response following vaccination of C57BL/6 mice 170 (n=5 per group) with LUNAR-COV19 or conventional mRNA. At day 7 post-vaccination, 171 spleens were harvested and assessed for CD8 and CD4 T cells by flow-cytometry. The CD8+ 172 T cell CD44+CD62L-effector/memory subset was significantly expanded in LUNAR-173 COV19 vaccinated mice compared to those given either PBS or conventional mRNA vaccine 174 ( Figure 3A-B) . There was no statistically significant difference in the proportion of CD4+ T 175 effector cells in these animals ( Figure 3C ). IFNγ+ CD8+ T cells (with 2 µg and 10 µg doses) 176

and IFNγ+ CD4+ T cells (in 0.2 µg and 10 µg) were proportionately higher, as found using 177 intracellular staining (ICS) with flow cytometry, in LUNAR-COV19 as compared to 178 conventional mRNA vaccinated animals ( Figure 3D-F) . vaccination. This trend contrasted sharply with mice that received the conventional mRNA 207 vaccine where in BALB/c mice antibody levels plateaued after day 10 post-vaccination; 208 although increasing S-specific IgG levels were observed in conventional mRNA-vaccinated 209 C57BL/6 mice these were universally lower than those that received LUNAR-COV19. 210 211 In depth characterization of the SARS-CoV-2 specific IgG response in vaccinated animals 212 was conducted at day 30 post-immunization to assess which regions of S protein are targeted. 213

IgG endpoint titers were estimated to full ectodomain S protein, S1, S2 and receptor binding 214 domain (RBD) regions. As expected for both vaccine candidates the majority of SARS-CoV-215

were also detected to S2 protein ( Figure 4F-G) . However, LUNAR-COV19 elicited IgG 217 endpoint titers were universally and significantly higher compared to those produced by 218 conventional mRNA vaccination (Figure 4F-G) . Notably, IgG that bind the RBD of S 219 protein, which is an immunodominant site of neutralizing antibodies [26, 27] , were also 220 higher in LUNAR-COV19 compared to conventional mRNA vaccinated animals. It is also 221 noteworthy that at lower doses, conventional mRNA vaccine but not LUNAR-COV19 222 struggled to elicit high SARS-CoV-2 specific IgG titers in the more Th1 dominant C57BL/6 223 mouse strain ( Figure 4G) . Taken collectively, a single dose of LUNAR-COV19 induced 224 significant differences in immune gene expression and superior cellular immune responses in 225 draining lymph nodes compared to the conventional mRNA vaccine and consequently greater 226 and more prolonged humoral immune responses. 227

We assessed both the binding strength (avidity) and the neutralizing ability of the antibody 229 response elicited by these vaccine constructs. Serum IgG avidity was measured at day 30 230 post-vaccination using a modified Luminex immuno-assay with 8M urea washes. LUNAR-231 COV19 elicited higher avidity S protein-specific IgG in both mouse models at all tested 232 doses ( Figure 4H ). These differences were observed, with the exception of 0.2 µg in 233 BALB/c, across all doses ( Figure 4H ), indicating that LUNAR-COV19 elicited better quality 234 antibodies, suggesting superior affinity maturation with the LUNAR-COV19 vaccine. 235

Neutralization of live SARS-CoV-2 by serum from vaccinated animals was assessed using 237 the plaque reduction neutralization test (PRNT). At day 30 LUNAR-COV19 vaccinated 238 BALB/c mice showed a clear dose-dependent elevation in PRNT50 titers; 4 out of 5 (80%) of 239 mice in the 10 µg LUNAR-COV19 group showed PRNT50 titers greater than 320, which was 240 the upper limit of our dilution ( Figure 4I ). Similar dose-dependent trends in PRNT50 titers 241 were also found in C57BL/6 mice although in these animals, the PRNT50 titers of several 242 animals exceeded 320 even with the lowest 0.2 µg dose vaccination ( Figure 4I ). In sharp 243 contrast, PRNT50 titers in animals inoculated with the conventional mRNA vaccine construct 244

were, except for one C57BL/6J mouse that received 10 µg dose, all <20 ( Figure 4I) . 245

Unexpectedly but encouragingly, PRNT50 and PRNT70 titers of LUNAR-COV19 vaccinated 246 BALB/c mice continued to rise between day 30 and day 60 after a single vaccination ( Figure  247 4J-K) and at both time points for doses ≥2.0 µg. These titers were comparable to PRNT70 248 titers for sera from convalescent COVID-19 patients ( Figure 4K) . 249

We also found that the S protein IgG titers positively correlated with PRNT50 titers with 251 LUNAR-COV19 vaccinated mice in both mouse models ( Figure 4L ). Similar positive 252 correlations were also observed with IgG against S1 and RBD (Supplementary Figure 1) . 253

By contrast, we found no correlation between IgG and PRNT50 titers in conventional mRNA 254 vaccinated mice ( Figure 4L ). Taken collectively, our antibody response analyses suggest that 255 the higher PRNT50 titers following vaccination with LUNAR-COV19 are not only strongly 256 associated with the amount of IgG produced but are also a factor of the superior quality of the 257 anti-SARS-CoV-2 antibodies produced following vaccination with LUNAR-COV19. 258

A safety concern for a coronavirus vaccine is the risk of vaccine-associated immune 261 Additionally, we used ICS to investigate the production of IFNγ (Th1 cytokine) and IL4 (Th2 276 cytokine) by CD4+ T cells in spleens at day 7 post vaccination C56BL/6J mice. As was 277 described above, compared to conventional mRNA vaccination, IFNγ levels were 278 significantly greater in LUNAR-COV19 vaccinated animals ( Figure 3F ). IL4 expression in 279 CD4 T cells were slightly higher with conventional mRNA as compared to LUNAR-COV19 280 at 0.2 and 2.0 µg doses ( Figure 5C ). In comparing the IFNγ and IL4 levels in individual 281 mice, we found that the ratios of IFNγ/IL4 in CD4+ T cells for both LUNAR-COV19 and 282 conventional mRNA vaccinated mice were universally above 1 ( Figure 5D ). The ratio of 283

IFNγ/IL4 in CD4+ T cells in mice given the 0.2 and 2.0 µg doses were significantly greater 284 with LUNAR-COV19 than conventional mRNA vaccination ( Figure 5F ). However, the 285 elevated ratios at these doses were due to a decrease in IL4 expression at levels below 286 background (i.e. PBS control mice), rather than reduced IFNγ and hence Th1 activity. Taken 287 collectively, our data show that LUNAR-COV19 produced a Th1 biased adaptive immune 288 response. 289 290

Finally, we tested the efficacy of LUNAR-COV19 in protecting against infection and 292 mortality in a lethal SARS-CoV-2 challenge model. Transgenic hACE2 mice immunized 293 with either PBS, or 2 µg or 10 µg of LUNAR-COV19 vaccine were intranasally challenged 294 with live SARS-CoV-2 virus (5x10 4 TCID50) at day 30 post-vaccination. This was the same 295 isolate as that used for our PRNT assays. Mice were then divided into two groups: one group 296 was tracked for weight, clinical scores and survival; a second group of mice were euthanized 297 at 5 days post injection (dpi) and viral loads assessed in the respiratory tract (trachea to lung) 298 and brain ( Figure 6A ). Measurement of PRNT70 titers confirmed the generation of 299 neutralizing antibodies in LUNAR-COV19-vaccinated hACE2 mice ( Figure 6B ). 300

Irrespective of tested dosages, mice that received the LUNAR-COV19 vaccine showed 301 unchanged weight and no clinical sign, while the PBS mice showed significant drop in 302 weight and increased clinical scores upon challenge with wild-type SARS-CoV-2 ( Figure  303 6C-D). LUNAR-COV19 vaccination at both 2 µg and 10 µg doses fully protected hACE2 304 mice from an otherwise 100% mortality at day 7 post-challenge ( Figure 6E ). Assessment of 305 tissue viral load at day 5 post-challenge found minimal to no SARS-CoV-2 RNA ( Figure 6F ) 306 in contrast to unvaccinated animal controls. Although viral RNA was detectable at very low 307 levels in some animals, this was not associated with any presence of infectious viral particles, 308 so most like represents viral RNA fragments rather than intact viral RNA genomes. No 309 detectable infectious virus was found in either the respiratory tracts or brains of LUNAR-310 COV19 vaccinated animals ( Figure 6G ). By contrast, unvaccinated animals showed 4 and 8 311 logs of infectious SARS-CoV-2 in the respiratory tract and brain, respectively ( Figure 6G) . 312

Collectively, these data show that a single dose of LUNAR-COV19 vaccine induced robust 313 humoral and cellular immune responses that led to complete protection of hACE2 mice from 314 a lethal SARS-CoV-2 challenge. 315

The pandemic of COVID-19 has necessitated rapid development of vaccines. Encouragingly, 318 several COVID-19 vaccine candidates are now in clinical trials and more are entering first-in-319 human trials. However, the majority of vaccine candidates being developed require two or 320 more doses for sufficient adaptive immune responses. Requirement for a second shot could 321 complicate compliance rate in mass vaccination campaigns and results in fewer subjects 322 vaccinated per batch, thereby reducing the efficiency of vaccination. Hence, a single dose 323 vaccine that generates robust and sustained cellular and humoral immunity, without elevating 324 the risk of vaccine-mediated immune enhancement, remains an unmet need. 

A human codon-optimized spike (S) glycoprotein gene of SARS-CoV-2 (GenBank 384 accession: YP_009724390) was cloned into plasmids pARM2922 and pARM2379 for 385 generation of SARS-CoV-2 Spike expressing STARR and conventional mRNA, respectively. 386

The STARR plasmid also encoded for the Venezuela equine encephalitis virus (VEEV) non-387 structural proteins nsP1, nsP2, nsP3 and nsp4, which together form the replicase complex that bulk formulation is aseptically filled into glass vials, stoppered, capped, and frozen at -70 ± 417 10°C. Analytical characterization included measurement of particle size and polydispersity 418 using dynamic light scattering (ZEN3600, Malvern Instruments), pH, Osmolality, RNA 419 content and encapsulation efficiency by a fluorometric assay using Ribogreen RNA reagent, 420 RNA purity by capillary electrophoresis using fragment analyzer (Advanced Analytical), 421 lipid content using HPLC,. 422

Hep3b cells (seeded in 6-well plates at a density of 7 X 10 5 cells/well, a day before) were 424 transfected with purified IVTs (2.5 μg conventional mRNA and 2.5 μg STARR ) by 425

Lipofectamine MessengerMax transfection reagent (Thermo Fisher Scientific) according to 426

the manufacturer's instruction. The cells were harvested the next day with a hypotonic buffer 427 (10 mM Tris-HCl, 10 mM NaCl supplemented with protease inhibitor cocktail (Roche) ) 428 followed by sonication. Samples were deglycosylated followed by treatment with PNGase F 429 (New England Biolabs) according to the manufacture's instruction. 430

The protein lysate (10 μg) was resolved on a 7.5% NuPAGE Tris-Acetate gel (Thermo Fisher 431 Scientific), and the spike protein expression was analyzed by LI-COR Quantitative Western 432

Blot system using a rabbit antibody detecting S1 (40150-T62-COV2, Sino Biologic) and a 433 mouse antibody for S2 region (GTX632604, GeneTex) along with appropriate secondary 434 antibodies (goat anti-rabbit 800 and goat anti-mouse 680). Longitudinal IgM and IgG responses in BALB/c and C57BL/6 were measured using an in-535

house Luminex Immuno-assay. Similar Luminex Immuno-assays have been previously 536 described for antibody detection against SARS-CoV-2 antigens [45, 46] . Briefly, Magpix 537

Luminex beads were covalently conjugated to insect-derived HIS-tagged SARS-CoV-2 538 whole Spike protein (SinoBiologicals) using the ABC coupling kit (Thermo) as per 539 manufacturer's instructions. Beads were then blocked with 1%BSA, followed by incubation 540 with serum (diluted at 1:2000 in block) for 1 hr at 37C. Beads are then washed and SARS-541

CoV-2 Spike-specific mouse antibodies were detected using the relevant biotinylated 542 secondary antibody (i.e. anti-mouse IgM-biotin and anti-mouse IgG-biotin (Southern 543 Biotech) for IgM and IgG assessment, respectively) with streptavidin-PE (Southern Biotech). 544

Antibody binding to Spike were then measured on a Magpix instrument as median 545 fluorescence intensity (MFI). Spike antigen quantity on beads were also probed with anti-546 6xHIS-PE antibodies and all MFI values were then corrected to Spike antigen quantity to 547 account for experiment to experiment variation. 548 549

IgG endpoint titers to mammalian-derived SARS-CoV-2 Spike, Spike domain 1 (S1), spike 551 domain 2 (S2) and receptor binding domain (RBD) at day 30 sera post-immunization were 552 measured using Luminex ImmunoAssay. Assay was conducted as described above, with the 553 modification of serially diluting serum 10-fold from 200 to 2x10 8 . Similarly, IgG subclass 554 endpoint titers (i.e. IgG1 and IgG2a in BALB/c and IgG1 and IgG2c in C57BL/6) were 555 measured against mammalian-derived SARS-CoV-2 Spike protein using serially diluted 556 mouse sera (5-fold from 200 to 3.1x10 6 ) and secondary antibodies anti-IgG1-biotin, anti-557

IgG2a-biotin or anti-IgG2b-biotin (Southern Biotech). Four parameter logistic (4PL) curves 558 were fitted to the measured MFI data from serially diluted sera, and three times the 559 background (i.e. 3x MFI with no serum) was used as a threshold cutoff to estimate endpoint 560 titers. 561 562

Avidity index of IgG to SARS-CoV-2 Spike protein at day 30 sera post-immunization was 564 estimated using the Luminex ImmunoAssay. Assay was conducted as described above with 565 the minor modification of following bead incubation with serum (diluted at 1:2000) with 566 either a 10 min PBS or 8M urea wash. Avidity Index was estimated by subtracting 567

background MFI from all sample values, and then dividing MFI with 8M Urea wash by MFI 568 with PBS wash. 569 570

Neutralization sero-conversion was assessed at day 10 and 20 post-immunization in BALB/c 573 using a virus neutralization assay as previously described [47] . Briefly, sera were diluted to 574 1:20 in culture media, mixed at a 1:1 ratio with a Singaporean clinical isolate of live SARS-575

CoV-2 virus, isolate BetaCoV/Singapore/2/2020 (GISAID accession code EPI_ISL_406973) 576

and incubated for 1 hr at 37C. Virus-antibody immune-complexes were then added to Vero-577 E6 cells (ATCC) in 96-well plates, and incubated at 37C. Five days later, plates were 578 assessed under a microscope for cytopathic effect (CPE) of the cells. 579

Neutralization of live SARS-CoV-2 was measured by PRNT at day 30 post-vaccination in 582 both BALB/c and C57BL/6 mice. Similar protocols have been published previously for 583 SARS-CoV-2 [48]. Briefly, mouse sera were serially diluted from 1:20 to 1:320 in culture 584 media and incubated with the Singapore isolate of SARS-CoV-2 virus for 1 hr at 37C. Virus-585 antibody mixtures were then added to Vero-E6 cells in 24-well plates, incubated for 1-2 hrs, 586 then overlayed with carboxymethyl cellulose (CMC) and incubated at 37C under 5% CO2. At showing Nanostring counts per 50ng RNA of selected IFN and inflammatory genes. 

COVID-19) Dashboard. 2020. 606 2. Bank, W. The Global Economic Outlook During the COVID-19 Pandemic: A Changed 607

Herd Immunity: Understanding COVID-19. Immunity

Draft landscape of COVID-19 candidate vaccines

The COVID-19 vaccine development landscape

Developing Covid-19 Vaccines at Pandemic Speed

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against 618

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5

COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human 624 trial

Understanding the role of innate immunity in the mechanism 626 of action of the live attenuated Yellow Fever Vaccine 17D

Systems biology approach predicts immunogenicity of the yellow fever 629 vaccine in humans

Programming the magnitude and persistence of antibody responses with 631 innate immunity

The COVID-19 vaccine development landscape

The promise of mRNA vaccines: a biotech and industrial perspective. 635 NPJ Vaccines

Optimization of Lipid Nanoparticles for Intramuscular Administration of 637 mRNA Vaccines

Formulation and Delivery Technologies for mRNA Vaccines

Amplifying RNA Vaccine Development

Cross-reactive antibodies enhance live attenuated virus infection for 643 increased immunogenicity

Early molecular correlates of adverse events following yellow fever 645 vaccination

Metabolic perturbations and cellular stress underpin susceptibility to 647 symptomatic live-attenuated yellow fever infection

Granzyme B regulates antiviral CD8+ T cell responses

The endogenous Toll-like receptor 4 agonist S100A8/S100A9 651 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer

APRIL and TALL-I and receptors BCMA and TACI: system for regulating 654 humoral immunity

CXCR3 in T cell function

Interaction between antibody-diversification enzyme AID and 658 spliceosome-associated factor CTNNBL1

The receptor binding domain of the viral spike protein is an 660 immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection 663 from disease in a small animal model

Impact of immune enhancement on Covid-19 polyclonal hyperimmune 665 globulin therapy and vaccine development. EBioMedicine

Severe acute respiratory syndrome-associated coronavirus vaccines 667 formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung 668 eosinophilic immunopathology

A Highly Immunogenic, Protective, and Safe Adenovirus-Based 670

Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model

Isotype-Specific Plasma Cell Function

Longitudinal dynamics of the human B cell response to the yellow fever 17D 676 vaccine

Sustained antigen availability during germinal center initiation enhances 678 antibody responses to vaccination

Slow Delivery Immunization Enhances HIV Neutralizing Antibody and 681

Germinal Center Responses via Modulation of Immunodominance

Immune responsiveness, tolerance and dsRNA: implications 684 for traditional paradigms

Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant

Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA 688 Vaccine: Implications for Vaccine Design

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with 690

COVID-19 Disease and Unexposed Individuals

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed 692 humans

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, 694 and uninfected controls

Engineered alphavirus replicon vaccines based on known attenuated viral 696 mutants show limited effects on immunogenicity

Mucosal and systemic adjuvant activity of alphavirus replicon 698 particles

Systemic delivery of factor IX messenger RNA for protein replacement 700 therapy

Dengue virus induces PCSK9 expression to alter antiviral responses and 702 disease outcomes

Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the 704 highly pathogenic human coronaviruses SARS-CoV and MERS-CoV

Distinct early serological signatures track with SARS-CoV-2 survival

A SARS-CoV-2 surrogate virus neutralization test based on antibody-709 mediated blockage of ACE2-spike protein-protein interaction

An evaluation of COVID-19 serological assays informs future 711 diagnostics and exposure assessment

Schematic diagram 718 of the SARS-CoV-2 self-replicating STARR RNA (LUNAR ® -COV19) and conventional 719 mRNA vaccine constructs. The STARR construct encodes for the four non-structural 720 proteins, ns1-ns4, from Venezuelan equine encephalitis virus (VEEV) and the unmodified 721 full-length pre-fusion spike (S) protein of SARS-CoV-2. The mRNA construct also codes for 722 the same SARS-CoV-2 full length spike S protein. B) Physical characteristics and RNA 723 trapping efficiency of the LNP encapsulating conventional mRNA and LUNAR-COV19 724 vaccines. C) Western blot detection of SARS-CoV-2 S protein following transfection of 725 HEK293 cells with LUNAR-COV19 and conventional mRNA. D)

Balb/c mice (n=3/group) were injected IM with 0.2 728 µg, 2.0 µg and 10.0 µg of STARR RNA or conventional mRNA formulated with the same 729 lipid nanoparticle. Luciferase expression was measured by in vivo bioluminescence on days 730 1, 3 and 7 post-IM administration

Clinical Scores, mouse weights and transcriptomic analysis of immune genes 734 following vaccination with LUNAR-COV19 or conventional mRNA SARS-CoV-2 735 vaccine candidates. A) C57BL/6 mice (n=5/group) were immunized with either PBS, 736 mRNA or LUNAR-COV19 (doses 0.2 µg, 2 µg or 10 µg), weight and clinical scores 737 assessed every day, bled at day 1 post-immunization, sacrificed at 7 days post-vaccination 738 and lymph nodes harvested. Gene expression of inflammatory genes and immune genes were 739 measured in whole blood (at day 1) and lymph nodes (at day 7), respectively. B) Expression 740 of IFN and inflammatory response genes in whole

Principal component analysis (PCA) of 742 immune gene expression following vaccination with conventional mRNA or LUNAR-743 COV19 at doses D) 0.2 µg, E) 2 µg and F) 10 µg. Volcano plots of fold change of LUNAR-744 COV19 versus conventional mRNA (x-axis) and Log10 P-value of LUNAR-COV19 versus 745 conventional mRNA (y-axis) for doses G) 0.2 µg, H) 2 µg and I) 10 µg. Study design 746 schematic diagram created with BioRender.com. Weights of lymph nodes were compared 747 between groups using a two

Cellular immune responses following vaccination with LUNAR-COV19 and 751 conventional mRNA. C57BL/6 mice (n=5 per group) were immunized with 0.2 µg, 2.0 µg, 752 or 10.0 µg of LUNAR-COV19 or conventional mRNA via IM, sacrificed at day 7 post-753 vaccination and spleens analyzed for cellular T cell responses by flow-cytometry and 754 ELISPOT. A-B) CD8 + and C) CD4 + T effector cells were assessed in vaccinated animals 755 using surface staining for T cell markers and flow-cytometry

G-I) SARS-CoV-2 S protein-758 specific responses to pooled S protein peptides were assessed using IFNγ ELISPOT assays 759 following vaccination with mRNA (H) or LUNAR-COV19 (I). Percentage of CD8+ cells, 760 CD4+ cells

Blood sampling was 772 conducted at baseline, and days 10, 19, 30, 40, 50 and 60 post-vaccination for BALB/c and 773 days 10, 20 and 30 for C57BL/6J. B-C) IgM and D-E) IgG against the SARS-CoV-2 S 774 protein over time, assessed using insect cell-derived whole S protein in a Luminex immuno-775 assay (measured as MFI). IgG endpoint titers to mammalian-derived whole S protein, S1, S2 776 and RBD proteins to mammalian-derived whole S protein at day 30 post-vaccination were

IgG at day 30 post-immunization was measured using 8M urea washes. I) Neutralizing 779 antibody (PRNT50 titers) at day 30 post-vaccination against a clinically isolated live

Gray dashed lines depict the serum 781 dilution range (i.e. from 1:20 to 1:320) tested by PRNT. J) PRNT50 and K) PRNT70 of 782 SARS-CoV-2 neutralization at day 30 and day 60 post-vaccination in BALB/c and 783 convalescent sera from COVID-19 patients. L) Correlation analysis of Spike-specific IgG 784 endpoint titers against SARS-CoV-2 neutralization (PRNT50)

SARS-CoV-2 spike-793 specific IgG subclasses and the ratio of IgG2a/c/IgG1 at 30 days post-vaccination with 794 LUNAR-COV19 and conventional mRNA in A) BALB/c and B) C57BL/6J mice. Th2 795 cytokine and Th1/Th2 skew in CD4 T cells at day 7 post-vaccination in C57BL/6J mice 796 measured by ICS as C) percentage of IL4+ CD4 T cells and D) ratio of IFNγ + /IL4 + CD4 + T 797 cells

Single dose of LUNAR-COV19 protects hACE2 mice against a lethal challenge 808 of SARS-CoV-2 virus. A) hACE2 transgenic mice were immunized with a single dose of 809 either PBS or 2 µg or 10 µg of LUNAR-COV19 (n=5 per group), then challenged with live 810 SARS-CoV-2 at 30 days post-vaccination, and assessed for either survival (with daily 811 weights and clinical scores) or sacrificed at day 5 post-challenge and measured lung and 812 brain tissue viral loads

at 28 days post-814 vaccination. C) Weight, D) clinical score and E) survival was estimated following challenge 815 with a lethal dose (5x10^5 TCID50) of live SARS-CoV-2 virus. F) Viral RNA and G) 816 infectious virus in the lungs and brain of challenged mice were measured with qRT-PCR or 817 plaque assay, respectively. PRNT70 and viral titers (RNA and plaque titers) were compared 818 across groups using the non-parametric Mann-Whitney U test. Weights and clinical scores at 819 different timepoints were compared between PBS and 10ug LUNAR-CoV19 immunized 820 mice using multiple t-tests

Correlation analysis of live SARS-CoV-2 neutralization against 836 binding IgG and IgG subclasses in BALB/c and C57BL/6J mouse strains. A) Spearman 837 correlation analysis of SARS-CoV-2 neutralization (PRNT50) against total IgG specific to 838 several SARS-CoV2 antigens, including S, S1, and RBD recombinant proteins. B) Spearman 839 correlation analysis of SARS-CoV-2 neutralization (PRNT50) against SARS-CoV2 S-840 specific IgG subclasses